Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 72 от 240

Набира участници Фаза 3

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

Alzheimer Disease

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

Начало: 10.07.2025 Край: 08.12.2028 Възраст: 55–90 г.

Argentina, Brazil, Bulgaria +12 Bristol-Myers Squibb NCT07011732

Набира участници Фаза 2

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population

Metastatic Oral Cavity Carcinoma Recurrent Oral Cavity Carcinoma Stage IVC Lip and Oral Cavity Cancer AJCC v8

This phase II trial gathers information on the feasibility, safety, and effect of giving methotrexate, erlotinib, and celecoxib in treating oral cavity cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic) among rural Midwest patients. Methotrexate is in a class of medications called antimetabolites. It is also a type of antifolate. Methotrexate stops cells from using folic acid to make deoxyribonucleic acid and may kill tumor cells. Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein called EGFR that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving the combination of methotrexate, erlotinib, and celecoxib may be feasible, safe, and effective in treating rural Midwest patients with recurrent/metastatic oral cavity cancer.

Начало: 09.07.2025 Край: 30.06.2028 Възраст: от 18 г.

United States Mayo Clinic NCT06997068

Набира участници

Optimizing the Diagnosis of Pneumocystis in Immunocompromised Patients

Pneumocystis Immunocompromised Patients

Evaluate new diagnostic methods using qPCR on non-invasive samples, compared with reference techniques for the positive diagnosis of pneumocystis (PcP) in immunocompromised patients

Начало: 08.07.2025 Край: 08.07.2027 Възраст: от 18 г.

France Assistance Publique - Hôpitaux de Paris NCT06890078

Набира участници

Evaluating the Effects of an Exercise Intervention on the Gut Microbiota in Stage II-III Colorectal Cancer Survivors

Stage II Colorectal Cancer AJCC v8 Stage III Colorectal Cancer AJCC v8 Colorectal Carcinoma

This trial evaluates the effects a moderate-to-vigorous exercise intervention has on the bacterial make-up of the gastrointestinal tract (gut microbiota) in survivors of stage II-III colorectal cancer (CRC). Data shows that the gut microbiota composition and function may be drivers of CRC. High levels of exercise are associated with improved CRC prognosis and survival. While data suggests that exercise has the potential to influence gut microbiota composition and function, it is not known whether these effects contribute to improved CRC prognosis. This clinical trial evaluates the effects an exercise intervention has on gut microbiota and how these effects relate to CRC progression and patient-reported outcomes.

Начало: 08.07.2025 Край: 01.07.2027 Възраст: 18–70 г.

United States Fred Hutchinson Cancer Center NCT05930496

Набира участници Фаза 2

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Metastatic Hormone-sensitive Prostate Cancer

This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor (ARPI, abiraterone or enzalutamide) in participants with metastatic Hormone Sensitive Prostate Cancer (mHSPC) and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and PK data from participants randomized in the study will be evaluated

Начало: 07.07.2025 Край: 19.10.2035 Възраст: от 18 г. Лечение

Australia, Brazil, Canada +12 Novartis Pharmaceuticals NCT06991556

Набира участници

Nurturing Outreach for Understanding and Reducing Inpatient Security of Health

Food Insecurity

Food insecurity is the lack of consistent access to the food needed for a healthy life. Food insecurity among families whose child has been hospitalized is a critical problem affecting a large, vulnerable population. The purpose of this study is to identity the most effective ways to help those families with food insecurity.

Начало: 07.07.2025 Край: 01.12.2026

United States Wake Forest University Health Sciences NCT07010289

Набира участници Фаза 2

A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis

Ulcerative Colitis

This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Ulcerative Colitis. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Ulcerative Colitis. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.

Начало: 07.07.2025 Край: 17.10.2029 Възраст: 18–75 г. Лечение

Australia, China, Czechia +9 Sanofi NCT06975722

Набира участници Фаза 4

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Relapsing Multiple Sclerosis Primary Progressive Multiple Sclerosis

The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with primary progressive multiple sclerosis (PPMS).

Начало: 04.07.2025 Край: 23.04.2027 Възраст: 18–55 г.

China Hoffmann-La Roche NCT07483450

Набира участници Фаза 1/2

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

Castration-Resistant Prostatic Cancer Metastasis

The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about: * The safety of the study treatment and if people tolerate it. * A safe dose level of I-DXd that can be used with other treatments. * Participant levels of prostate specific antigen (PSA) during treatment.

Начало: 03.07.2025 Край: 01.04.2031 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +16 Merck Sharp & Dohme LLC NCT06863272

Набира участници Фаза 2

A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

AL Amyloidosis

This is a multicenter open-label, phase 2 study in participant with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the benefit of teclistamab

Начало: 02.07.2025 Край: 01.09.2028 Възраст: от 18 г. Лечение

Australia, France, Germany +3 European Myeloma Network B.V. NCT06649695

Набира участници Фаза 2

Ketamine, SGB and Combination Treatment for TBI

Posttraumatic Headache Posttraumatic Stress Disorder

Post-Traumatic Stress Disorder (PTSD) and traumatic brain injury (TBI) with associated headache are amongst the most common injuries sustained by our deployed forces in Iraq and Afghanistan, as well as in more recent conflicts in Eastern Europe and the Middle East. This study aims to determine whether a procedural intervention (stellate ganglion block (SGB)) or medication (ketamine), alone or in combination, can alleviate PTSD and TBI-associated headache. Determining efficacious treatments in a randomized, double-blind, placebo-controlled, multicenter study trial may improve quality of life in those with TBI and PTSD, and identifying factors associated with treatment outcome (personalized medicine) may enhance selection, thereby improving the risk: benefit and cost-effectiveness ratios. Primary Objectives: 1. To determine the efficacy of SGB and ketamine infusion as stand-alone treatments for TBI-related headache; 2. To determine the efficacy of SGB and ketamine infusion as stand-alone treatments for PTSD; 3. To determine the comparative effectiveness of SGB and ketamine infusion, and the effect of combination treatment on TBI-related headache and PTSD; 4. Exploratory Aim 1: To determine the effects of SGB, ketamine infusion, and the combination on structural and functional MRI, biomarker levels and pain thresholds and tolerance; 5. Exploratory Aim 2: To identify factors associated with treatment responders overall and for individual treatment groups. Secondary Objectives: 1. Exploratory Aim 1: To determine the effects of SGB, ketamine infusion, and the combination on structural and functional MRI, biomarker levels and pain thresholds and tolerance (Biomedical levels and MRI not included at Northwestern University Site). 2. Exploratory Aim 2: To identify factors associated with treatment responders overall and for individual treatment groups.

Начало: 02.07.2025 Край: 30.04.2028 Възраст: от 18 г.

United States Northwestern University NCT06608277

Набира участници

Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

Systemic Lupus Erythematosus

PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users) is a prospective, observational cohort study designed to evaluate the association between anifrolumab exposure during pregnancy and subsequent adverse maternal, fetal, and infant outcomes. This study will fulfil an FDA post-marketing requirement.

Начало: 01.07.2025 Край: 15.04.2031

United States AstraZeneca NCT06659029

Набира участници

Inspiratory Muscle Training After Vertebroplasty in Osteoporotic Fracture Patients

Osteoporotic Vertebral Compression Fractures Restrictive Pulmonary Disorders Inspiratory Muscle Weakness Postoperative Pulmonary Function

This study investigates the long-term effects of inspiratory muscle training (IMT) on pulmonary function, functional capacity, and quality of life in individuals with osteoporotic vertebral compression fractures who have undergone percutaneous vertebroplasty. Participants aged 50 and older, diagnosed with osteoporosis and having undergone thoracic vertebroplasty within the past 3 months, will be randomly assigned to either an intervention group (IMT + standard rehabilitation) or a control group (standard rehabilitation only). The primary outcome measure is spirometry-based pulmonary function. Secondary outcome measures include inspiratory muscle strength, functional walking capacity (6-minute walk test), diaphragmatic structure and elasticity, and quality of life (SGRQ, NHP). This randomized controlled trial will be conducted at the Cardiopulmonary Rehabilitation Unit of Nuh Naci Yazgan University and aims to provide scientific evidence for integrating IMT into routine post-vertebroplasty rehabilitation protocols.

Начало: 01.07.2025 Край: 30.04.2026 Възраст: от 50 г.

Turkey (Türkiye) Istinye University NCT07024095

Набира участници

Lentiviral Gene Therapy for CGD

Chronic Granulomatous Disease

This is a Phase I/II clinical trial of gene therapy for treating Chronic Granulomatous Disease using a high-safety, high-efficiency, self-inactivating lentiviral vector TYF to functionally correct the defective gene. The objectives are to evaluate the safety and efficacy of the TYF-CGD gene transfer clinical protocol.

Начало: 01.07.2025 Край: 31.12.2029

China Shenzhen Geno-Immune Medical Institute NCT03645486

Набира участници Фаза 1/2

Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells

Cancer

The primary objectives are to evaluate the safety and efficacy of infusion of autologous tumor associated antigen-specific engineered immune effector cells (EIE).

Начало: 01.07.2025 Край: 31.12.2029 Възраст: 1–80 г.

China Shenzhen Geno-Immune Medical Institute NCT03535246

Набира участници Фаза 1/2

Immunotherapy Treating GI Cancer

Cancer

The primary objectives are to evaluate the safety and efficacy of infusion of autologous gastro-intestinal (GI) cancer antigen-specific engineered immune effector cells (EIE).

Начало: 01.07.2025 Край: 31.12.2028 Възраст: 1–80 г.

China Shenzhen Geno-Immune Medical Institute NCT03614650

Набира участници

Video-Based Patient Navigation to Support Cervical Cancer Screening Among Black Women

Uterine Cervical Neoplasms

The goal of this clinical trial is to test whether an interactive, video-based patient navigation program can improve cervical cancer screening among African American women who are currently overdue for screening. The main questions it aims to answer are: Can an interactive video navigation tool (mNav), when paired with in-person navigation, improve screening adherence compared to a standard educational video alone? Does the intervention improve knowledge, reduce barriers, and increase intentions to get screened? Researchers will compare participants who receive both the interactive video (guided by an on-screen navigator) and in-person navigation to those who receive only a standard educational video to see if the tailored support increases screening rates. Participants will: Complete two phone surveys (one at the beginning and one six months later) Be randomly assigned to one of two groups: One group will receive an interactive video experience tailored to their concerns plus support from an in-person navigator The other group will receive a standard educational video designed for African American women Have their clinic records reviewed six months later to check for cervical cancer screening completion

Начало: 01.07.2025 Край: 31.03.2027 Възраст: 21–65 г.

United States ISA Associates, Inc. NCT07011836

Набира участници

DLPFC and Sympathetic Reactivity in RPL With Anxiety

Recurrent Pregnancy Loss Without Current Pregnancy Anxiety Disorder

We propose an exploratory clinical study (NEURO-CARD-2) that employs simultaneous functional near-infrared spectroscopy (fNIRS) and electrocardiography (ECG) to investigate interhemispheric dysfunction in the dorsolateral prefrontal cortex (DLPFC) and its relationship with autonomic sympathetic activation in women with recurrent pregnancy loss (RPL) and comorbid anxiety. Using a standardized multisensory aversive emotional stimulation paradigm, the study will assess cortical and cardiac responses within the framework of the Brain-Heart-Emotion interaction model. The objective is to identify neurobiological signatures underlying emotion-autonomic dysregulation in this population, thereby informing future development of precision-targeted interventions.

Начало: 01.07.2025 Край: 30.04.2026 Възраст: 18–45 г.

China Shenyang Medical College NCT07045818

Набира участници

Randomized Study of a Dematerialized Management for Post-Emergency Gynecological Follow-Up

Genital Diseases, Female Ectopic Pregnancy Uncertain Viability of Pregnancy Abortion, Missed +1

The GYNAB study aims to compare patient satisfaction and clinical outcomes between dematerialized post-emergency gynecological follow-up using a connected health app and traditional in-person follow-up. Conducted by Drs. Laëtitia CAMPIN and Louis MARCELLIN at Hôpital Cochin, it is sponsored by Assistance Publique - Hôpitaux de Paris. The main objective is to assess patient satisfaction at day 7 on a scale from 0 to 10, considering symptom management, follow-up quality, and task performance. Secondary objectives include comparing satisfaction at day 28, PROM-ED scores for symptom relief, understanding, reassurance, and care planning at days 7 and 28, hospitalization rates, unscheduled consultations, surgical interventions, total hospital time by day 28, and physician satisfaction at 28 days. This randomized trial involves women aged 18-60 needing follow-up for conditions like genital infections, non-complicated ectopic pregnancies, unlocated pregnancy, first trimester metrorrhagia, miscarriages , and severe vomiting before 12 weeks. Inclusion criteria are women aged 18-60 needing specified follow-up. Exclusion criteria are severe clinical intolerance, severe criteria ultrasound findings, non-French speakers, and inability to use digital applications. The intervention group uses a connected health app for data collection and communication, logging symptoms and test results, with medical team notifications for urgent updates. The control group receives traditional in-person follow-up with scheduled consultations and emergency contact information. The study hypothesizes that digital follow-up will improve patient experience, reduce hospital visits, and provide comparable or superior satisfaction and clinical outcomes. The results could promote broader digital health adoption in various medical fields.

Начало: 30.06.2025 Край: 30.07.2027 Възраст: 18–60 г.

France Assistance Publique - Hôpitaux de Paris NCT06615843

Набира участници Фаза 3

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

Gangliosidoses, GM2 Gangliosidosis, GM1

An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of GM1 gangliosidosis or GM2 gangliosidosis

Начало: 30.06.2025 Край: 04.11.2027 Възраст: от 4 г. Лечение

Argentina, Australia, Brazil +13 Azafaros A.G. NCT07082543

1 … 70 71 72 73 74 … 240